Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus Infection
The Journal of Infectious Diseases2004Vol. 190(6), pp. 1119–1126
Citations Over TimeTop 10% of 2004 papers
Yuchun Nie, Guangwen Wang, Xuanling Shi, Hong Zhang, Qiu Yan, HE Zhong-ping, Wei Wang, Gewei Lian, Yin Xiaolei, Liying Du, Lili Ren, Jianwei Wang, Xiong He, Taisheng Li, Hongkui Deng, Ding Mingxiao
Abstract
NAbs to SARS-CoV are broadly elicited in patients with SARS and, according to their kinetics, may correlate with viral load during the early stages of the disease. These results suggest that it is possible to develop effective vaccines against SARS and that NAbs provide a potential strategy for treating patients with SARS.
Related Papers
- → 2019 Novel Coronavirus (2019-nCoV) Pneumonia(2020)159 cited
- → Racing Towards the Development of Diagnostics for a Novel Coronavirus (2019-nCoV)(2020)32 cited
- → And now for something completely different: from 2019-nCoV and COVID-19 to 2020-nMan(2020)27 cited
- → The COVID-19 conundrum: SARS-CoV-2 is not present in bile(2020)7 cited